Precision Biosciences Stock Price, News & Analysis

Precision BioSciences (Nasdaq: DTIL) has received favorable rulings from the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) in two patent interference proceedings, affirming nine patents related to its allogeneic CAR T cell platform. The PTAB dismissed a third party's claim that it invented the technology, allowing Precision’s patents to remain intact. The patented technology allows for consistent and cost-effective CAR T cell production. The patents were issued in 2018 and involve a single-step genome editing process aimed at enhancing cancer immunotherapy.

Precision BioSciences (Nasdaq: DTIL) announced the appointment of Alex Kelly as Chief Corporate Affairs Officer, a newly created role overseeing investor relations and corporate communications. Kelly brings extensive experience from Allergan and other prominent companies, focusing on impactful messaging and business transformations. CEO Matt Kane highlighted Kelly's alignment with the company’s mission in developing innovative CAR T and gene editing therapies. Precision’s pipeline includes multiple CAR T products and gene correction candidates, indicating a significant growth trajectory.

DURHAM, N.C., Sept. 28, 2020 – Precision BioSciences, a clinical stage biotechnology company listed on Nasdaq as DTIL, announced its participation in two upcoming virtual investor conferences. The events include the Chardan 4th Annual Genetic Medicines Conference on October 5, 2020, from 8:30 – 9:00 AM ET, and the Jefferies Cell Therapy Summit, also on the same day, from 5:30 – 6:00 PM ET. Webcasts of the presentations will be available on the company's website, with an archived replay accessible for about 30 days post-event.

Precision BioSciences (Nasdaq: DTIL), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences on October 5, 2020. The conferences include the Chardan 4th Annual Genetic Medicines Conference, scheduled for 8:30 AM ET, and the Jefferies Cell Therapy Summit, starting at 5:30 PM ET. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days post-event. Precision BioSciences utilizes its ARCUS genome editing platform to develop innovative therapies for genetic and infectious diseases.

Precision BioSciences (Nasdaq: DTIL) announced a clinical trial collaboration with SpringWorks Therapeutics (Nasdaq: SWTX) to evaluate PBCAR269A, an allogeneic CAR T cell therapy targeting BCMA, in combination with nirogacestat, a gamma secretase inhibitor. The trial aims to improve outcomes in relapsed or refractory multiple myeloma patients and is set to commence in early 2021. Precision will cover all development costs, with the FDA granting Fast Track Designation to PBCAR269A. This collaboration seeks to enhance the efficacy of BCMA-targeted therapies through combined treatment strategies.

Precision BioSciences (Nasdaq: DTIL) expands its CAR T development agreement with Servier, adding two hematological and two solid tumor targets to its pipeline. This collaboration enhances the ongoing development of PBCAR0191, targeting CD19 in treating non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. Precision aims to utilize its ARCUS genome editing platform for early-stage research, with potential milestone payments expected in 2020 and 2021. The partnership aims to innovate 'off-the-shelf' CAR T therapies for broader cancer treatment applications.

Precision BioSciences has received Fast Track Designation from the FDA for its CAR T cell therapy, PBCAR269A, aimed at treating relapsed/refractory multiple myeloma. This designation follows the previously granted Orphan Drug Designation, expediting the clinical development process. PBCAR269A is undergoing a Phase 1/2a trial, with a focus on assessing safety and efficacy at escalating doses. The company leverages its proprietary ARCUS technology to optimize CAR T therapies, ultimately aiming to make treatments more accessible for patients.

Precision BioSciences (Nasdaq: DTIL) announced its participation in three upcoming investor conferences, showcasing its ARCUS® genome editing platform. The schedule includes the Wells Fargo Virtual Healthcare Conference on September 10, 2020, at 12:40 PM ET, the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, at 1:30 PM ET, and the Morgan Stanley Global Healthcare Conference on September 17, 2020, at 8:45 AM ET. Live webcasts will be available on the company’s website, with replays accessible for 30 days.

Precision BioSciences (Nasdaq: DTIL) announced its Q2 2020 financial results and updates on clinical trials. The company initiated a Phase 1/2a trial for PBCAR269A, a CAR T candidate for multiple myeloma. However, patient enrollment delays related to COVID-19 have postponed updated interim data for PBCAR0191 until Q4 2020. Financially, total revenue decreased to $1.1 million from $5.4 million YoY, driven by reduced collaboration revenue. Operating expenses rose, resulting in a net loss of $32.7 million, or $(0.63) per share, compared to $(0.39) per share in 2019.